Progression of itching intensity and expression of growth factor proteins in skin of people suffering from atopic dermatitis under the influence of ultraviolet phototherapy

Cover Page


Cite item

Full Text

Abstract

Study of progression of itching intensity and expression of growth factor proteins in skin of people suffering from atopic dermatitis under the influence of narrowband (311Nm) phototherapy. Material and methods. 30 patients with atopic dermatitis were treated by using narrowband (311Nm) phototherapy. SCORAD index was used to assess the severity of the clinical responses. Itching intensity was assessed using visual analogue scale. Expression of growth factor of nerves, semaphorine-3A, amphiregulin, and PGP9.5, a protein marker for nerve fibers, was investigated by means of indirect immunofluorescence. Results. Increased expression level of nerves growth factor, decreased expression level of semaphorine-3A, and increase in the number, average length and luminous intensity of PGP9.5+ -nerve fibers were found in the patients’ epidermis. Course of narrowband (311 Nm) phototherapy resulted in a decrease of the severity of the disease and itching intensity, and semaphorine-3A expression increase, reduction of number and average length of nerve fibers in the epidermis. A direct correlation relationship between the itching intensity and expression level of nerve growth factor, number and average length of PGP9.5+ -nerve fibers in the epidermis as well as an inverse correlation relationship between itching intensity and expression level of semaphorine-3A in the epidermis were found. Conclusion. Treating patients suffering from atopic dermatitis with narrowband (311 Nm) phototherapy leads to a decrease of the itching intensity associated with a decreased intensity of innervation of the epidermis. This decrease in course of phototherapy is facilitated by decrease of nerve growth factor expression level and increase of semaphorine-3A expression.

About the authors

A. A. Kubanova

State Research Center of Dermatovenereology and Cosmetology

Author for correspondence.
Email: info@cnikvi.ru
Russian Federation

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

V. V. Chikin

State Research Center of Dermatovenereology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

V. A. Volnukhin

State Research Center of Dermatovenereology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

V. A. Smolyannikova

I.M. Sechenov First Moskow State Medical University

Email: noemail@neicon.ru
Russian Federation

M. A. Nefedova

State Research Center of Dermatovenereology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

References

  1. Koblenzer C.S. Itching and the atopic skin. J Allergy Clin Immunol. 1999; 104: S109-S113.
  2. Tominaga М., Takamori К. An update on peripheral mechanisms and treatments of itch. Biol Pharm Bull. 2013; 36 (8): 1241-1247.
  3. Albers K.M., Wright D.E., Davis B.M. Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of the peripheral nervous system. J Neurosci. 1994; 14: 1422-1432.
  4. Nilsson A., Kanje M. Amphiregulin acts as an autocrine survival factor for adult sensory neurons. Neuroreport. 2005; 16: 213-218.
  5. Dontchev V.D., Letourneau P.C. Nerve growth factor and semaphorin 3A signaling pathways interact in regulating sensory neuronal growth cone motility. J Neurosci. 2002; 22: 6659-6669.
  6. Kamo A., Tominaga М., Tengara S. et al. Inhibitory effects of UV-based therapy on dry skin-inducible nerve growth in acetone-treated mice. J Dermatol Sci. 2011; 62: 91-97.
  7. Tintle S., Shemer A., Suarez-Farinaz M. et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011; 128 (3): 583-593.
  8. Reynolds N.J., Franklin V., Gray J.C. et al. Narrowband ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001; 357: 2012-2016.
  9. Gambichler T., Othlinghaus N., Tomi N.S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009; 160: 652-658.
  10. Wallengren J., Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibers. Acta Derm Venereol. 2004; 84 (2): 111-115.
  11. Katunina O.R., Chikin V.V., Znamenskaya L.F., Inoyatova L.A. Role of neuromediators in the development of skin irritation in patients with atopic dermatitis. Vestnik Dermatologii i Venerologii 2013; (5): 91-101. [
  12. Катунина О.Р., Чикин В.В., Знаменская Л.Ф., Иноятова Л.А. Роль нейромедиаторов в развитии воспаления в коже больных атопическим дерматитом. Вестн дерматол венерол 2013; (5): 91-101].
  13. Emtestam L., Hagströmer L., Dou Y.C. et al. PGP9.5 distribution patterns in biopsies from early lesions of atopic dermatitis. Arch Dermatol Res. 2012; 304 (10): 781-785.
  14. Tominaga M, Ogawa H, Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol. 2008; 158: 842-844.
  15. Yamaguchi J., Aihara M., Kobayashi Y. et al. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci. 2009; 53 (1): 48-54.
  16. Tominaga M., Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. 2014; 41: 205-212.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2015 Kubanova A.A., Kubanov A.A., Chikin V.V., Volnukhin V.A., Smolyannikova V.A., Nefedova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies